Better follow-up and testing after acute kidney injury
Improving Patient Assessment After Acute Kidney Injury (AKI)
This project will test different blood tests, a measured kidney clearance, body measurements, and patient interviews to see which best help adults recovering from hospitalised acute kidney injury.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | University of Nottingham Academic / other |
| Locations | 1 site (Derby, Derbyshire) |
| Trial ID | NCT07569588 on ClinicalTrials.gov |
What this trial studies
The work has three linked parts: a biochemical comparison of creatinine, cystatin C and iohexol renal clearance to determine the most reliable measure of kidney function after AKI; structured questionnaires and semi‑structured interviews to document patients' symptoms and experiences; and participatory workshops to develop practical follow‑up and support recommendations. Adults who had AKI in hospital are invited to attend around 60–90 days after their peak creatinine for blood tests, body composition measurements, questionnaires, or interviews as appropriate. The study excludes people on dialysis, with a renal transplant, pregnant or breastfeeding, or unable to give consent. Findings will be used to propose clearer testing protocols and patient-centred support plans for post‑AKI care.
Who should consider this trial
Good fit: Adults aged 18–85 who had hospitalised AKI (stage 2–3, or stage 1 lasting at least 7 days) and are 60–90 days past their peak creatinine are the intended participants.
Not a fit: People already on dialysis, with a kidney transplant, pregnant or breastfeeding, or unable to give informed consent are unlikely to gain benefit from joining this project.
Why it matters
Potential benefit: If successful, the project could produce clearer follow-up tests and patient support plans that help detect ongoing kidney problems earlier and improve recovery after AKI.
How similar studies have performed: Previous studies have shown cystatin C and measured clearance can add information beyond creatinine, but combining those comparisons with patient interviews and co‑development workshops is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Observational study workstream * Age 18-85 years * AKI stage 2 or 3 during hospital admission OR AKI stage 1 of at least 7 days duration during hospital admission * 60-90 days after peak creatinine Qualitative interview workstream * Age 18-85 years * AKI during hospital admission * 60-90 days after peak creatinine Participatory workshop workstream * Age 18-85 years * Relevant experience (as assessed by the investigator) which could include personal experience of an episode of hospitalised AKI as a patient of carer, experience of managing AKI or related problems in a professional capacity or knowledge of a particular community. Exclusion Criteria: Observational study workstream * Inability to give informed consent * No baseline creatinine available in previous 12 months * Pregnancy or breastfeeding * Current treatment with dialysis * Renal transplant * Pacemaker in situ * Previous amputation * Allergy to Omnipaque contrast agent (WP1 only) * Manifest thyrotoxicosis (WP1 only) * Ascites or significant (grade 3 to 4) peripheral oedema, defined as ≥6 mm pit, lasting for \>1 minute after 5-second compression over tibia or medial malleolus (WP1 only) Qualitative interview workstream * Inability to give informed consent * No baseline creatinine available in previous 12 months * Current treatment with dialysis * Renal transplant * Receiving palliative care Participatory workshop workstream * Inability to give informed consent * Inability to communicate in English (the qualitative workshops will be held in English)
Where this trial is running
Derby, Derbyshire
- University Hospitals of Derby and Burton NHS Foundation Trust — Derby, Derbyshire, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Nicholas Selby — University of Nottingham
- Study coordinator: Kerry Horne Dr, BMBCh
- Email: kerry.horne@nottingham.ac.uk
- Phone: +44 01332 788262
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.